Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Transplant: its role in 2021 and optimization

Meral Beksac, MD, of Ankara University, Ankara, Turkey, explains the current role of transplant and it’s optimization for the treatment of multiple myeloma in the current treatment landscape. Dr Beksac talks on the EMN02 trial (NCT01208766) which compared autologous stem cell transplantation (ASCT) versus bortezomib, melphalan, prednisone (VMP) with or without bortezomib, lenalidomide and dexamethasone consolidation therapy, and lenalidomide maintenance for patients with newly diagnosed multiple myeloma. This study showed that double transplant prolonged progression-free survival for high-risk patients in comparison to single transplant, and that earlier transplant significantly improved outcomes compared to later transplant. Dr Beksac also gives an overview of the latest clinical data from studies such as the MUKnine OPTIMUM trial (ISRCTN16847817), the Cardamon trial (NCT02315716), and the FORTE trial (NCT02203643), talking further on transplantation and induction regimens. Finally, Dr Beksac discusses the role of measurable residual disease (MRD) in the field of myeloma, and comments on how it may be integrated with transplantation. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Dr Beksac reports the following disclosures: participation in the CEPHEUS and IMROZ studies